Featured Research

from universities, journals, and other organizations

Protein Identified That Turns Off HIV-fighting T Cells

Date:
November 13, 2008
Source:
Rockefeller University Press
Summary:
In HIV-infected patients, the body's immune system is unable to fight off the virus. A new study shows that T cells in HIV-infected individuals express a protein called TIM-3, which inactivates their virus killing capacity. Blocking this protein, the study suggests, might one day help patients to eliminate HIV as well as other chronic infections.

In HIV-infected patients the body's immune system is unable to fight off the virus. A new study to be published online on November 10th in the Journal of Experimental Medicine shows that T cells in HIV-infected individuals express a protein called TIM-3, which inactivates their virus killing capacity. Blocking this protein, the study suggests, might one day help patients to eliminate HIV as well as other chronic infections.

Large numbers of virus-fighting T cells can be found in the blood of most chronically infected HIV patients. However these cells eventually become exhausted and cannot function. To identify the cause of this exhaustion, a team of researchers at the University of Toronto, lead by Mario Ostrowski, compared blood from healthy individuals and HIV patients. In the patients, TIM-3 was found on a large number of HIV-specific T cells, and the number of TIM-3-positive cells increased with the severity of infection.

Under normal circumstances, exposing T cells to bits of virus causes the cells to replicate and produce virus-killing chemicals. Cells expressing TIM-3, however, were unreactive and TIM-3 was to blame; disrupting its signals restored the cells' virus-fighting functions. TIM-3 normally gets expressed on T cells after they carry out their normal function, perhaps as a way to turn the cells off and thus prevent excessive inflammation. But during HIV infection, persistent TIM-3 expression may help the virus avoid T cell attack.

Whether HIV infection itself induces or sustains TIM-3 is not known. Still, blocking the protein might be a useful way to control virus that persists despite antiretroviral therapy.


Story Source:

The above story is based on materials provided by Rockefeller University Press. Note: Materials may be edited for content and length.


Cite This Page:

Rockefeller University Press. "Protein Identified That Turns Off HIV-fighting T Cells." ScienceDaily. ScienceDaily, 13 November 2008. <www.sciencedaily.com/releases/2008/11/081110112058.htm>.
Rockefeller University Press. (2008, November 13). Protein Identified That Turns Off HIV-fighting T Cells. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2008/11/081110112058.htm
Rockefeller University Press. "Protein Identified That Turns Off HIV-fighting T Cells." ScienceDaily. www.sciencedaily.com/releases/2008/11/081110112058.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins